Latest news with #VeevaBasics
Malaysian Reserve
21-05-2025
- Business
- Malaysian Reserve
More Than 75 Emerging Biotechs Use Veeva Basics Across Clinical, Regulatory, and Quality
Delivers pre-configured, pre-validated software that can scale with the needs of fast-growing companies BARCELONA, Spain, May 20, 2025 /PRNewswire/ — Veeva Systems (NYSE: VEEV) today announced that Veeva Basics is being used by more than 75 biotechs to gain efficiency and reduce costs across clinical, regulatory, and quality. With standardized applications, biotechs are going live with industry-leading software in weeks and gaining a system that can scale as they expand their business. The rapid adoption of Veeva Basics signals a shift from disparate entry-level tools toward complete, best-of-breed solutions that can support biotechs today and as they grow. Designed specifically for fast-growing companies, Veeva Basics provides pre-configured and pre-validated solutions. This enables fast deployment and adoption regardless of company size. With clinical, regulatory, and quality solutions available, Veeva is adding two new applications for biotechs: Veeva CTMS Basics for clinical trial management, including milestones, monitoring, enrollment, issue resolution, and site communications. Veeva Submissions Publishing Basics for building, publishing, and transmitting regulatory submissions in a single system. 'More biotechs are adopting Veeva Basics in North America and Europe, driving savings in time, cost, and effort,' said Steve Harper, general manager of Veeva Basics. 'Our approach to deliver pre-configured and pre-validated solutions that can go live quickly is gaining momentum, and we're adding new clinical and regulatory solutions to meet the needs of high-growth companies. With complete cloud applications, biotechs can ensure they are always current and benefit from the latest features.' Veeva CTMS Basics and Submissions Publishing Basics are available today in North America and Europe. Built on the proven Vault Platform, Veeva Basics applications allow customers to scale their technology infrastructure as they grow. For more on Veeva Basics, visit What biotechs are saying about Veeva Basics: 'I believe Veeva Basics is a game changer, giving smaller biotech companies access to the same modern and connected applications that are typically only available to larger organizations,' said Ian Hodgson, Ph.D., chief operating officer at Corbus Pharmaceuticals, Inc. 'As our company continues to grow, I am confident that Veeva's platform can scale with us and help ensure we remain up to date as regulatory requirements evolve.' 'As we expand our studies to a larger scale, Veeva eTMF Basics gives us more control of our data and process to ensure inspection readiness,' said Joe Thornton, associate director, clinical operations at Scancell. 'Having an industry-leading solution with pre-configured best practices as our foundation for trials will help drive speed and innovation as we continue to develop novel immunotherapies.' 'The global support and training provided with Veeva Basics helps us gain maximum value from Veeva's industry solution,' said Rebecca Deng, Ph.D., associate director, regulatory affairs and QA systems at Terns Pharmaceuticals. 'With a simple path to go live and validation, Veeva Basics has delivered significant time and resource savings.' About Veeva SystemsVeeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world's largest biopharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit Veeva Forward-looking StatementsThis release contains forward-looking statements regarding Veeva's products and services and the expected results or benefits from use of our products and services, including certain of our new solutions and applications that are still under development or not generally available. These statements are based on our current expectations. Actual results, availability, and any future events relating to these products and services could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-K for the fiscal year ended January 31, 2025, which you can find here (a summary of risks which may impact our business can be found on pages 9 and 10), and in our subsequent SEC filings, which you can access at Contact: Jeremy WhittakerVeeva Systems+ View original content:
Associated Press
20-05-2025
- Business
- Associated Press
Spotline V-Assure Platform Enables Pre-Validation for Veeva Basics Releases
SAN JOSE, Calif., May 20, 2025 /PRNewswire/ -- Spotline, Inc., a Veeva-certified product, services, and AI partner, today announced that Veeva Systems is using its V-Assure platform to enable faster, pre-validated software releases for Veeva Basics—the pre-configured solution designed to help emerging biotechs achieve rapid deployment and built-in GxP compliance. Veeva used Spotline's V-Assure platform to accelerate the delivery of the last three releases of Veeva Basics for clinical, regulatory, and quality. V-Assure automated testing for these applications, providing emerging biotech customers with documentation to support the Basics Production Qualification. How Spotline Supports Veeva Basics' Mission for Biotech Speed and Compliance To help Veeva deliver Veeva Basics efficiently as a turnkey application, Spotline: This proactive, automation-first approach helped ensure that every release was audit- and inspection-ready to support accelerated development and release management of Veeva Basics. 'By using Spotline's V-Assure testing platform, we can deliver complete qualification documentation across our Veeva Basics applications,' said Steve Harper, General Manager of Veeva Basics. 'Automating testing helps us to move faster and provide testing and documentation on behalf of our customers. This saves time and effort while accelerating application delivery for emerging biotech.' Automated Validation Across Veeva Basics Applications With Spotline's V-Assure one-touch automated testing within each release cycle, Veeva successfully delivered audit- and inspection-ready validation documentation for its Veeva Basics applications in clinical, regulatory, and quality. Through the validation process, Veeva automated more than 500 test case executions across its Veeva Basics applications. 'Supporting the Veeva Basics team through three major releases has showcased how automated validation—when done right—can deliver speed and reliability,' said Sid Sahoo, CEO of Spotline, Inc. 'V-Assure is helping life sciences organizations modernize their validation processes and unlock faster adoption of compliant solutions.' Meet Us at the Veeva R&D and Quality Summits Spotline will demonstrate the latest version of V-Assure, including its enhanced integrations with Veeva Validation Management, at the upcoming Veeva R&D and Quality Summits in Europe and the U.S. Attendees are encouraged to schedule a demo at to explore how V-Assure can transform their validation operations. About Spotline Inc. Spotline Inc. is a Veeva-certified partner delivering innovative validation, automation, and integration solutions for life sciences. Through products like V-Assure, Spotline enables biotech and pharmaceutical companies to accelerate compliance, reduce risk, and focus on strategic innovation. For more information about Spotline, please visit Contact Info Jeff Andrist Spotline Inc. Email: [email protected] View original content to download multimedia: SOURCE Spotline, Inc.
Yahoo
20-05-2025
- Business
- Yahoo
More Than 75 Emerging Biotechs Use Veeva Basics Across Clinical, Regulatory, and Quality
Delivers pre-configured, pre-validated software that can scale with the needs of fast-growing companies PLEASANTON, Calif., May 20, 2025 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that Veeva Basics is being used by more than 75 biotechs to gain efficiency and reduce costs across clinical, regulatory, and quality. With standardized applications, biotechs are going live with industry-leading software in weeks and gaining a system that can scale as they expand their business. The rapid adoption of Veeva Basics signals a shift from disparate entry-level tools toward complete, best-of-breed solutions that can support biotechs today and as they grow. Designed specifically for fast-growing companies, Veeva Basics provides pre-configured and pre-validated solutions. This enables fast deployment and adoption regardless of company size. With clinical, regulatory, and quality solutions available, Veeva is adding two new applications for biotechs: Veeva CTMS Basics for clinical trial management, including milestones, monitoring, enrollment, issue resolution, and site communications. Veeva Submissions Publishing Basics for building, publishing, and transmitting regulatory submissions in a single system. "More biotechs are adopting Veeva Basics in North America and Europe, driving savings in time, cost, and effort," said Steve Harper, general manager of Veeva Basics. "Our approach to deliver pre-configured and pre-validated solutions that can go live quickly is gaining momentum, and we're adding new clinical and regulatory solutions to meet the needs of high-growth companies. With complete cloud applications, biotechs can ensure they are always current and benefit from the latest features." Veeva CTMS Basics and Submissions Publishing Basics are available today in North America and Europe. Built on the proven Vault Platform, Veeva Basics applications allow customers to scale their technology infrastructure as they grow. For more on Veeva Basics, visit What biotechs are saying about Veeva Basics:"I believe Veeva Basics is a game changer, giving smaller biotech companies access to the same modern and connected applications that are typically only available to larger organizations," said Ian Hodgson, Ph.D., chief operating officer at Corbus Pharmaceuticals, Inc. "As our company continues to grow, I am confident that Veeva's platform can scale with us and help ensure we remain up to date as regulatory requirements evolve." "As we expand our studies to a larger scale, Veeva eTMF Basics gives us more control of our data and process to ensure inspection readiness," said Joe Thornton, associate director, clinical operations at Scancell. "Having an industry-leading solution with pre-configured best practices as our foundation for trials will help drive speed and innovation as we continue to develop novel immunotherapies." "The global support and training provided with Veeva Basics helps us gain maximum value from Veeva's industry solution," said Rebecca Deng, Ph.D., associate director, regulatory affairs and QA systems at Terns Pharmaceuticals. "With a simple path to go live and validation, Veeva Basics has delivered significant time and resource savings." About Veeva SystemsVeeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world's largest biopharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit Veeva Forward-looking StatementsThis release contains forward-looking statements regarding Veeva's products and services and the expected results or benefits from use of our products and services, including certain of our new solutions and applications that are still under development or not generally available. These statements are based on our current expectations. Actual results, availability, and any future events relating to these products and services could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-K for the fiscal year ended January 31, 2025, which you can find here (a summary of risks which may impact our business can be found on pages 9 and 10), and in our subsequent SEC filings, which you can access at Contact: Deivis MercadoVeeva View original content to download multimedia: SOURCE Veeva Systems Sign in to access your portfolio
